Cerca
Cerca
+

CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

default_image

AdnKronos
  • a
  • a
  • a

Dai blog